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Objective: Currently there are no clinical or laboratory measures that accurately predict 
progression of skin fibrosis and organ involvement in patients with systemic sclerosis 
(SSc). The goal of this study is to identify skin biomarkers in early diffuse cutaneous SSc 
patients, to prognosticate the progression of skin fibrosis.  
Methods: We analyzed clinical data and skin biopsy gene expression from 38 placebo 
patients, part of the Roche faSScinate phase 2 study of tocilizumab in SSc. RNA 
samples were analyzed using nCounter technology. A trajectory model, based on the 
modified Rodnan skin score was used to describe three skin disease trajectories over 
time. We examined the association of skin gene expression with trajectory groups of 
skin score using the Chi-square test. We used logistic regression to examine the 
prognostic power of each gene identified.  
Results: We found that placebo treated patients with high CD14, SERPINE1, IL13RA1, 
CTGF, and OSMR mRNA expression at baseline were more likely to have progressive 
skin score trajectories. We also found that those genes were prognostic for the risk of 
skin progression and IL13RA1, OSMR and SERPINE 1 performed the best. 
Conclusion: Skin gene expression of biomarkers associated with macrophages (CD14, 
IL13RA1) and TGFβ activation (SERPINE1, CTGF, OSMR) are prognostic for 
progressive skin disease. These biomarkers might help to guide decisions about which 
patients should be considered for aggressive therapies and/or for clinical trials. 
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Short Title: Prognostic biomarkers in diffuse cutaneous systemic sclerosis   
 
Introduction 
 Currently there are no clinical or laboratory measures that accurately predict 
progression of skin fibrosis and organ involvement in patients with SSc. Several studies, 
including retrospective cohort analyses and randomized clinical trials, have shown that 
the severity of skin fibrosis, as assessed by MRSS, is predictive of disease mortality [1] 
[2]. In particular, Shand et al. defined three distinct skin score trajectory subgroups, 
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using latent variable modeling, and showed that patients with the worst skin score 
trajectory have significantly increased mortality [3].  
 Several clinical and serological measures have been associated with progressive 
skin disease.  It is generally accepted that the fastest rates of skin disease progression 
are recorded early in the disease [4]. A recent observational study from the EUSTAR 
has shown that joint synovitis, short disease duration (less than 15 months) and low 
MRSS at baseline predict more progressive skin fibrosis [5]. Anti-RNA-polymerase III 
(anti-Pol3) is associated with scleroderma renal crisis (SRC) and more severe skin 
disease, though less interstitial lung disease (ILD) [4] [6]. Despite these findings there 
remains no broadly accepted methodology for assessing the likelihood of progressive 
skin disease and no validated prognostic biomarkers of skin disease evolution, limiting 
patient risk-stratification and consequently the ability to select patients with progressive 
disease for innovative therapies.  
 We recently reported that CD14 expression correlates strongly with progressive 
skin disease [7]. Using data collected from the faSScinate study, an international trial of 
tocilizumab (TCZ) in SSc [8], we describe trajectory patterns of skin score change over 
time using a group-based modeling approach in placebo (PBO) treated patients and 
assessed several potential prognostic biomarkers associated with these skin score 
changes. In addition, we also examined the relation of each biomarker to the change in 
skin scoreover time.   
Methods 
  
Study design and participants  
Samples and clinical data for the discovery cohort used in this study were part of the 
faSScinate phase 2 study (ClinicalTrials.gov: NCT01532869). Briefly, the FaSScinate 
study was a randomized, double-blind, placebo-controlled phase 2 study of tocilizumab 
(162 mg subcutaneously weekly) in systemic sclerosis patients aged 18-year or older, 
with progressive disease of less than 5 years’ duration since their first non-Raynaud’s 
sign or symptom. In the current analysis, we focused on the FaSScinate patients treated 
with placebo (PBO). Of these (n=44) we excluded six subjects. Two patients did not 
have a biopsy at baseline. One patient had only two MRSS values (at baseline and at 8 
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weeks) and discontinued the study at week 16. The other three excluded patients had a 
drop of MRSS of greater than 12 units in two sequential assessments, suggesting that 
the scoring MRSS trajectory in these patients would be unreliable.  
 
Skin biopsy gene expression analysis 
RNA samples, used for analysis of gene expression, were analyzed using nCounter 
technology (NanoString Technologies, Seattle, WA, USA). Expression of genes was 
normalized to 12 housekeeping genes. Of the 83 genes selected for confirmation 
expression analysis, 62 transcripts were significantly overexpressed and two were 
significantly underexpressed in SSc patients compared with healthy controls (t-test, 
Bonferroni correction for multiple comparisons). Microarray data from the faSScinate 
trial, used for selecting prognostic genes, has been deposited in NCBI GEO, ID# 
GSE106358. 
 
Statistical analysis  
 We described patterns of skin score change over time using a semiparametric 
mixture model [9]. Specifically, the distinctive trajectories of skin score were derived by 
modeling skin score as a function of time, i.e. the number of days in the study using a 
SAS Macro (PROC TRAJ) [10]. We assumed each trajectory of skin score had a linear 
pattern of decline and tested this assumption by including a quadratic term (i.e., testing 
for the possibility that change in skin score has a curved shape) and evaluated statistical 
significance of these terms for each trajectory group. Linear but not quadratic model 
terms were statistically significant (p <0.05); thus we only included a linear term in our 
final models. The probability of each trajectory membership for a subject was estimated 
from the group-based model.  Each subject was assigned to a specific trajectory group 
that had the highest estimated probability (i.e., posterior probability) compared with 
those of other trajectory groups. We used Bayesian information criteria (i.e., BIC) and 
Entropy (i.e., amount of classification error indexed by average posterior probability) to 
assess the model fit. In general, models with lower BIC values provide a better fit to the 
data, and Entropy statistics near 1 (above 0.8) convey a model with well-separated 
trajectories [9]. 
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 We divided expression of each gene into tertile groups. For expression of each 
gene we examined its association with trajectory groups of skin score using the Chi-
square test. In addition, we examined the association between each gene expression at 
baseline and skin score change over time from baseline using Generalized-Estimating 
Equations in SAS with the “exchange” option for the working correlation matrix. In the 
regression model, the lowest tertile of each gene expression measure was used as the 
referent group to test the difference in change in MRSS score. Finally, we collapsed 
regressive and stable trajectories into one group and modeled the predictive ability of 
each gene by logistic regression. Using SAS, we assessed the predictive ability of the 
model according to discrimination and calibration. Discrimination was assessed using 
area under the curve (AUC), with the guidelines suggesting that values of at least 0.70 
are needed for adequate prediction. Calibration was assessed using the Hosmer and 
Lemeshow test [11], where a significant result indicates poor calibration. Pearson 
correlations were calculated using Prism software (GraphPad Software, Inc.). 
Differences were considered significant at a P-value <0.05. 
Results  
Study patients 
 All patients enrolled in the faSScinate study met the 1980 American College of 
Rheumatology criteria for SSc, had active SSc of ≤5 years disease duration since their 
first non-Raynaud symptom, and a MRSS between 15 to 40. In addition, at screening, 
active progressive disease of <1 year’s duration was required—increase of ≥3 MRSS 
units, involvement of one new body area with increase in MRSS ≥2 units or two new 
body areas with increase in MRSS ≥1 unit, other documentation of worsening skin 
thickening in the previous 6 months, or ≥1 tendon friction rub plus ≥1 laboratory criterion 
(C-reactive protein [CRP] ≥10·0 mg/L, erythrocyte sedimentation rate ≥28 mm/h, or 
platelets ≥330×1000/µL)  [8]. The discovery cohort for the identification of prognostic 
biomarkers consisted of 38 patients from the PBO group (Table 1). For validation we 
studied microarray gene expression data from a second cohort of patients with diffuse 
cutaneous SSc (dcSSc, 20 patients in total). This group of 20 patients, which we have 
defined as the validation cohort, has similar clinical features to the discovery group. All 
the patients had diffuse cutaneous systemic sclerosis, and they are in their early phase 
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of the disease (less than 5 years from the first non Raynaud’s phenomenon symptom). 
However, patients in the validation group had some significant differences compared 
with those in the discovery group. First, patients in the validation group were treated with 
immunosuppressant drugs, whereas the patients from the discovery group received only 
placebo during the study. Second, all patients in the validation group had only two 
measurements of MRSS, one at baseline and another at 24 weeks. Third, patients in the 
discovery cohort met certain additional criteria to define disease activity, whereas those 
in the validation cohort did not [12]. 
 
Gene expression and correlation with MRSS  
 Microarray data generated as part of the clinical trial from mid-forearm skin 
biopsies were analyzed for genes that correlated most highly with the change in skin 
score from baseline to six months after treatment with placebo. From a microarray that 
was generated as part of the faSScinate study, we selected 83 genes that highly 
correlated with the change in skin score at 6 months (Supplementary Figure 1). 62 of 
these were over expressed in SSc patients compared to the healthy control. Most of 
these genes correlating most highly with the change in MRSS were in gene clusters 
identifiable as part of TGFβ/profibrotic-, IL6/STAT3-, or IFN-pathways; or associated with 
macrophages. Other genes of interest were also included in the nCounter panel, as 
described previously [8]. Gene expression from each of the patients was tested using 
Counter technology (Nanostring Technologies, Inc.) as described previously [8].  
 Using this gene expression data, we calculated the correlation coefficient (r) in 34 
of 38 placebo treated patients between gene expression at baseline and the change in 
MRSS at week 16 (4 patients were not included because of missing values at 16 weeks 
and/or at baseline). Based on this correlation, we clustered all the genes for which |r| 
>0.2 (Figure 1). By inspection these genes grouped into three different clusters. Two of 
the clusters (group A and group B) contained many recognizable genes based on known 
biological relevance: TGF-β/profibrotic genes (Figure 1; group A) and macrophage-
associated genes (Figure 1; group B). The third cluster contained genes without evident 
biological relationship (Figure 1; group C).  
We compared the correlation between baseline gene expression and the change 
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in MRSS in this cohort of patients, defined as the discovery group, with microarray data 
from a second cohort of dcSSc patients defined as the validation cohort. We found that 
the correlation coefficients had the same trend for many of the genes in both cohorts 
(Supplementary Table 1), even though the R-values were different between the two 
groups. This might be due to differences in clinical features between the two groups, as 
well as the two different methods used for the gene expression analyses (nanostring 
versus microarray).  
 From the group of the genes that we identified (Supplementary table 1) we chose 
seven genes for further analysis based on the strength of correlation between baseline 
gene expression and the change in MRSS in both discovery and validation cohorts of 
>|0.2|. Since expression of many of the genes correlated highly with each other, we 
limited our analysis of co-regulated genes to the genes showing the largest correlation 
coefficients. Notably expression levels of CD14, chemokine (C-C motif) ligand 2 (CCL2), 
CD163, Macrophage Scavenger Receptor 1 (MSR1) and membrane-spanning 4-
domains, subfamily a, member 4a (MS4A4A) were highly correlated and therefore we 
chose to focus on CD14 only. The following genes were analyzed further: CD14, 
interleukin 13 Receptor Alpha 1 (IL13RA1), SERPINE1, ONCOSTATIN M Receptor 
(OSMR), Connective Tissue Growth Factor (CTGF), Insulin Like Growth Factor Binding 
Protein 2 (IGFBP-2), and Interferon Regulatory Factor 7 (IRF7) (Table 2). All these 
genes were overexpressed in SSc patient skin compared to the healthy controls (Figure 
1).  
 
Descriptive Trajectory Data 
 As shown in Figure 2 we identified three trajectories of skin score change (y) over 
48 weeks: 12 (30%) showed a regressive trajectory (regressive patients: y=17.69773-
0.12504* weeks), 18 (45%) a stable trajectory (stable patients: y=25.02055 -0.08435* 
weeks), and 10 (25%) a progressive trajectory (progressive patients: y= 
31.12353+0.11507* weeks). The progressive trajectory group started with a higher 
average MRSS (30.65) than the other two trajectories and the average skin score 
increased 17.7% at the end of 48 weeks. The regressive group started with a lower 
average MRSS (19.93), which decreased 33.9% at the end of follow up period. The 
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stable group started with an intermediate average MRSS (26.12) and experienced a 
slight decline in MRSS (16.2%) over the same time period. The average posterior 
probability of allocating study participants into trajectories (i.e., entropy) was 
 
>0.97, 
indicating an excellent precision that individuals were assigned to their most likely 
trajectories. 
Association of Gene expression and Pattern of skin score progression 
 We examined the seven genes selected from the cluster groups (CD14, IL13RA1, 
SERPINE1, OSMR, CTGF, IGFBP-2, and IRF7) in relation to the trajectory of skin score 
over time. Subjects expressing high levels of CD14, IL13RA1, SERPINE1, OSMR and 
CTGF at baseline were more likely to be associated with a progressive trajectory of skin 
score (Table 3). No association was found between levels of either IRF7 or IGFBP2 
gene expressions with skin score trajectories. We further examined the performance of 
each of these genes as prognostic biomarkers of progressive versus stable/regressive 
skin disease. Expression of five genes (CD14, IL13RA1, SERPINE1, OSMR and CTGF) 
was prognostic for the risk of skin progression (Supplementary Table 2). IL13RA1 was 
performing the best, followed by OSMR and SERPINE1.  
 
Association of Gene expression and skin score change 
Expression of several genes, i.e., CD14, IL13RA1, SERPINE1, OSMR, and 
CTGF were also associated with skin score change over time from baseline.  Compared 
with those in the lowest tertile, patients in the highest tertile of CD14, IL13RA1, 
SERPINE1, OSMR, and CTGF showed an increased MRSS.  In contrast, the highest 
tertile of IGFBP2 appeared to show an improvement of MRSS over time (Table 4). 
Similar results were also observed in the validation group. 
 
Discussion 
 
 Predicting the trajectory of skin disease in dcSSc patients is currently difficult on 
the basis of clinical criteria [13]. Analyzing skin gene expression, we show that CD14, 
SERPINE1, IL13RA1, CTGF, and OSMR mRNA expression are prognostic for the 
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trajectory of skin disease in active dcSSc patients for one year following the skin biopsy. 
Thus, increased expression of these genes may serve as better markers than currently 
available methods for selecting patients with progressive skin disease. 
 In this study we utilized skin biopsy samples from patients treated with PBO in the 
Roche faSScinate phase 2 study of tocilizumab in SSc [8]. These samples provided a 
rare opportunity to examine prognostic biomarkers in a group of active dcSSc patients 
who were not treated with any immunosuppressive drug. However, the inclusion criteria 
for this study may have impacted the results. All patients had active dcSSc of ≤5years 
disease duration since their first non-Raynaud symptom, and a screening MRSS 
between 15 and 40. In addition, at screening, active progressive disease of <1 year’s 
duration was required as defined by an increase of ≥3 MRSS units, involvement of one 
new body area with increase in MRSS ≥2 units or two new body areas with increase in 
MRSS ≥1 unit, other documentation of worsening skin thickening in the previous 6 
months, or ≥1 tendon friction rub plus ≥1 laboratory crite rion (C-reactive protein [CRP] 
≥10·0 mg/L, erythrocyte sedimentation rate ≥28 mm/h, or platelets ≥330×1000/µL). 
Enriching for early active disease by these eligibility criteria may have led to enrollment 
of patients with more progressive disease. We found that the prognostic biomarkers 
identified using PBO-treated patients enrolled in the faSScinate study also showed 
trends in R-values that were prognostic in a cohort of patients from Boston University 
Medical Center (BUMC). The BUMC patient cohort had received treatment with a variety 
of immunosuppressive medications [12]. Thus, these prognostic biomarkers may have 
broader prognostic value in other patients with early diffuse SSc. However, it is also 
possible that these biomarkers may only act as predictors in the preselected faSScinate 
cohort. 
 Defining progressive skin disease, as defined by worsening MRSS, is important 
to enrich patients for clinical trials where separation between the control and active 
treatment groups over a relative short period of time (i.e. ≤1 year) is desirable . The three 
trajectory groups indicated that the patients most likely to progress showed high 
baseline MRSS. We found that only 25% of PBO treated patient showed a progressive 
trajectory, despite an effort to enrich the patient population for active disease. Similar 
results were found previously in a larger study in which 192 patients with dcSSc were 
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grouped using latent linear trajectory [3]. On the other hand, the trajectories we describe 
here appear, on the surface, to be discrepant with a recent study of European patients 
[14]. The most apparent possible reason for this difference would be in patient selection 
for the two studies. The EUSTAR database is an observational study that recruits 
patients with dcSSc with a broad range of disease durations, whereas faSScinate is a 
clinical trial of patients with early dcSSc with elevated acute-phase reactants. Thus, the 
differences in the study population characteristics may explain the difference between 
these studies and ongoing clinical trials, which have defined inclusion criteria based on 
the EUSTAR database, will provide further insights on enriching SSc study patients with 
progressive skin disease. 
 We show here that macrophage markers, CD14, IL13RA1, MSR1, CD163 and 
MS4A4A, correlate with progressive skin disease trajectories. Our current findings are in 
line with previous studies by our group, showing that the macrophage markers, SIGLEC-
1 and MRC1 (mannose receptor-1) are increased in lesional SSc skin [15 16]. In 
addition, we recently showed that changes in skin gene expression of MS4A4A 
correlates highly with changes in the MRSS, helping define a two-gene 
pharmacodynamic biomarker [17]. Further, in peripheral blood mononuclear cells, 
IL13RA1 gene expression correlates highly with pulmonary arterial hypertension in 
patients with limited cutaneous SSc [18]. Finally, we recently reported that SSc patient 
treatment with TCZ results in the down-regulation of skin CD14 expression [8]. Together 
these observations indicate an important function of macrophages in SSc tissue 
inflammation and fibrosis. As these cells are found surrounding blood vessels, these 
data suggest that macrophages bridge the fibrotic and vascular features with the 
pathology seen in SSc skin.  
 Two of the prognostic biomarkers identified here, SERPINE1 and CTGF, are 
strongly induced by TGF-β [19 20]. TGF-β has long been suspected as an important 
mediator of fibrosis in SSc as well as a variety of other fibrotic diseases, including renal, 
pulmonary, cardiac, and liver fibrosis [21-23]. These two genes were significantly 
decreased in patients treated with fresolimumab (anti-TGF-β antibody), further 
supporting the role of TGF-β in pathogenesis of this disease [17]. 
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 Finally, we identify OSMR, which forms the Oncostatin (OSM) receptor with the 
common signaling partner gp130, as a prognostic biomarker. OSM, an IL-6 family 
cytokine, is produced by a variety of immune cells, including macrophages, neutrophils 
and activated T cells [24]. It has been implicated in a number of biological processes 
including the induction of inflammation and the modulation of extracellular matrix (ECM). 
OSM is upregulated in the bronchoalveolar lavage fluid of patients with idiopathic 
pulmonary fibrosis and SSc [24] and increased in the serum of dcSSc patients [25].  
 In conclusion, patients with elevated expression of CD14, CTGF, IL13RA1, 
OSMR, and SERPINE1 at baseline are more likely to have progressive skin score 
trajectories. The use of these biomarkers might help to guide decisions about which 
patients should be considered for aggressive therapies and/or for clinical trials. This 
observation will be further explored in the ongoing phase 3 focuSSced study of TCZ in 
SSc patients (ClinicalTrials.gov: NCT02453256).  
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Table 1. Patient characteristics 
Values are mean±SD, number (%) or as indicated. All patients met the 1980 ACR 
criteria for systemic sclerosis (SSc). Disease duration was defined by the time since 
the first non-Raynaud’s symptom. (MRSS, modified Rodnan Skin Score). 
 
 
 
 
 
 
 
 
Characteristic PBO (N = 38) 
Age (Year)   
     Mean (SD) 47.2 (13.0) 
     Median (Range) 49.5 (19-69) 
Sex   
     Female (n) 78.9% (30) 
     Male (n) 21.1% (8) 
MRSS   
     Mean (SD) 25.1 (5.2) 
     Median (Range) 25 (15-37) 
Disease duration (Months)   
     Mean (SD) 19.8 (16.8) 
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Table 2. Comparison of correlations (r) between gene expression and changes of skin 
score in the discovery group and the validation group 
 
 
 
GENE 
 
DISCOVERY GROUP 
(r) 
VALIDATION GROUP 
(r) 
IL13RA1 0.6 0.25 
SERPINE1 0.54 0.31 
OSMR 0.52 0.27 
CTGF 0.45 0.23 
CD14 0.59 0.36 
IRF7 -0.2 -0.24 
IGFBP2 -0.44 -0.32 
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Table 3. Association of gene expression and trajectory of skin score over 
follow-up period 
Gene 
expression 
Skin Score Trajectories 
 Regressive      Stable     Progressive  
P value 
CD14    0.013 
    Low  5 6 1  
   Med 4 7 2  
   High 0 5 8  
IL13RA1    0.026 
   Low 4 7 1  
   Med 5 6 2  
   High 1 4 8  
SERPINE 1    0.049 
   Low 5 6 1  
   Med 4 6 3  
   High 1 4 8  
OSMR    0.058 
   Low 6 6 0  
   Med 2 6 5  
   High 2 5 6  
CTGF    0.020 
   Low 5 5 2  
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   Med 4 8 1  
   High 1 4 8  
IRF7    0.345 
   Low 5 6 1  
   Med 2 6 5  
   High 3 5 5  
IGFBP2    0.566 
   Low 3 4 5  
   Med 3 8 2  
   High 4 5 4  
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Table 4. Association of gene expression and skin score change over the time. 
 
 
Gene Expression 
Tertile groups 
 
 
Mean of skin score change 
(95% Confidence Intervals) 
 
P value 
CD14   0.0793 
Middle vs lowest  -0.28 (-3.46, 2.90)  0.86 
Highest vs lowest 3.48 (0.31, 6.66) 0.03 
   
IL13RA1   0.0532 
Middle vs lowest  1.63 (-1.51, 4.77) 0.31 
Highest vs lowest 4.08 (1.36, 6.80) 0.003 
   
SERPINE 1   0.0696 
Middle vs lowest  -0.74 (-3.99, 2.51) 0.65 
Highest vs lowest 3.16 (0.59, 5.72) 0.016 
   
OSMR   0.0184 
Middle vs lowest  1.07 (-1.93, 4.07) 0.48 
Highest vs lowest 4.08 (1.87, 6.29) 0.0003 
   
CTGF   0.0491 
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Middle vs lowest  -0.71 (-3.86, 2.44) 0.66 
Highest vs lowest 3.32 (0.87, 5.76) 0.008 
   
IRF7  0.4539 
Middle vs lowest  0.90 (-1.53, 3.32) 0.44 
Highest vs lowest -1.23 (-4.39, 1.93) 0.47 
   
IGFBP2  0.1241 
Middle vs lowest  0.37 (-1.94, 2.69) 0.75 
Highest vs lowest -3.10 (-6.29, 0.10)  0.058 
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